Best practices: Appropriate use of the new β-lactam/β-lactamase inhibitor combinations, ceftazidime-avibactam and ceftolozane-tazobactam in South Africa

Adrian J Brink¹, Jennifer Coetzee², Guy A Richards³, Charles Feldman⁴, Warren Lowman^{5

6

7}, Hafsah D Tootla⁸, Malcolm G A Miller⁹, Abraham J Niehaus¹⁰, Sean Wasserman^{11

12}, Olga Perovic^{13

14}, Chetna N Govind^{15

16}, Natalie Schellack¹⁷, Marc Mendelson¹¹

Affiliations

¹ Division of Medical Microbiology, Institute of Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
² Division of Microbiology, Ampath National Reference Laboratory, Centurion, South Africa.
³ Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
⁴ Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
⁵ Department of Clinical Microbiology, Pathcare/Vermaak Pathologists, Gauteng, South Africa, South Africa.
⁶ Department Clinical Microbiology and Infectious Diseases, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
⁷ Department of Clinical Microbiology and Infection Prevention and Control, Wits Donald Gordon Medical Centre, Johannesburg, South Africa.
⁸ Division of Medical Microbiology, National Health Laboratory Service, Red Cross War Memorial Children's Hospital, Cape Town, South Africa.
⁹ Division of Critical Care, Department of Anaesthesia and Perioperative Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
¹⁰ Department of Medical Microbiology, Ampath Laboratory Services, Cape Town, South Africa.
¹¹ Division of Infectious Diseases and HIV Medicine, Department of Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa.
¹² Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
¹³ National Institute for Communicable Disease, National Health Laboratory Services, Johannesburg, South Africa.
¹⁴ School of Pathology, Clinical Microbiology and Infectious Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
¹⁵ Department of Medical Microbiology, Lancet Laboratories, KwaZulu-Natal, Durban, South Africa.
¹⁶ Antimicrobial Research Unit, School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
¹⁷ Department of Pharmacology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.

PMID: 36338193
PMCID: PMC9634826
DOI: 10.4102/sajid.v37i1.453

Best practices: Appropriate use of the new β-lactam/β-lactamase inhibitor combinations, ceftazidime-avibactam and ceftolozane-tazobactam in South Africa

Adrian J Brink et al. S Afr J Infect Dis. 2022.

. 2022 Oct 20;37(1):453.

doi: 10.4102/sajid.v37i1.453. eCollection 2022.

Authors

Affiliations

¹ Division of Medical Microbiology, Institute of Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
² Division of Microbiology, Ampath National Reference Laboratory, Centurion, South Africa.
³ Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
⁴ Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
⁵ Department of Clinical Microbiology, Pathcare/Vermaak Pathologists, Gauteng, South Africa, South Africa.
⁶ Department Clinical Microbiology and Infectious Diseases, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
⁷ Department of Clinical Microbiology and Infection Prevention and Control, Wits Donald Gordon Medical Centre, Johannesburg, South Africa.
⁸ Division of Medical Microbiology, National Health Laboratory Service, Red Cross War Memorial Children's Hospital, Cape Town, South Africa.
⁹ Division of Critical Care, Department of Anaesthesia and Perioperative Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
¹⁰ Department of Medical Microbiology, Ampath Laboratory Services, Cape Town, South Africa.
¹¹ Division of Infectious Diseases and HIV Medicine, Department of Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa.
¹² Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
¹³ National Institute for Communicable Disease, National Health Laboratory Services, Johannesburg, South Africa.
¹⁴ School of Pathology, Clinical Microbiology and Infectious Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
¹⁵ Department of Medical Microbiology, Lancet Laboratories, KwaZulu-Natal, Durban, South Africa.
¹⁶ Antimicrobial Research Unit, School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
¹⁷ Department of Pharmacology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.

PMID: 36338193
PMCID: PMC9634826
DOI: 10.4102/sajid.v37i1.453

Abstract

Antibiotic stewardship of hospital-acquired infections because of difficult-to-treat resistant (DTR) Gram-negative bacteria is a global challenge. Their increasing prevalence in South Africa has required a shift in prescribing in recent years towards colistin, an antibiotic of last resort. High toxicity levels and developing resistance to colistin are narrowing treatment options further. Recently, two new β-lactam/β-lactamase inhibitor combinations, ceftazidime-avibactam and ceftolozane-tazobactam were registered in South Africa, bringing hope of new options for management of these life-threatening infections. However, with increased use in the private sector, increasing levels of resistance to ceftazidime-avibactam are already being witnessed, putting their long-term viability as treatment options of last resort, in jeopardy. This review focuses on how these two vital new antibiotics should be stewarded within a framework that recognises the resistance mechanisms currently predominant in South Africa's multi-drug and DTR Gram-negative bacteria. Moreover, the withholding of their use for resistant infections that can be treated with currently available antibiotics is a critical part of stewardship, if these antibiotics are to be conserved in the long term.

Keywords: Enterobacterales; Gram-negatives; Pseudomonas aeruginosa; antimicrobial stewardship; ceftazidime-avibactam; ceftolozane-tazobactam; β-lactam/β-lactamase inhibitor combinations.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no financial or personal relationships that may have inappropriately influenced them in writing this article.

Figures

**FIGURE 1**
Conceptual approach to β-lactamase inhibitor therapy for severe infections.

See this image and copyright information in PMC

References

1. Brink AJ, Richards G. Best practice: Antibiotic decision-making in ICUs. Curr Opin Crit Care. 2020;26(5):478–488. 10.1097/MCC.0000000000000752 - DOI - PubMed
1. Kadri SS, Adjemian J, Lai YL, et al. . Difficult-to-Treat Resistance in Gram-negative bacteremia at 173 US hospitals: Retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents. Clin Infect Dis. 2018;67(12):1803–1814. 10.1093/cid/ciy378 - DOI - PMC - PubMed
1. Brink AJ. Epidemiology of carbapenem-resistant Gram-negative infections globally. Curr Opin Infect Dis. 2019;32(6):609–616. 10.1097/QCO.0000000000000608 - DOI - PubMed
1. Perovic O, Ismail H, Quan V, et al. . Carbapenem-resistant Enterobacteriaceae in patients with bacteraemia at tertiary hospitals in South Africa, 2015 to 2018. Eur J Clin Microbiol Infect Dis. 2020;39(7):1287–1294. 10.1007/s10096-020-03845-4 - DOI - PubMed
1. Lowe M, Kock MM, Coetzee J, et al. . Klebsiella pneumoniae ST307 with bla OXA-181, South Africa, 2014-2016. Emerg Infect Dis. 2019;25(4):739–747. 10.3201/eid2504.181482 - DOI - PMC - PubMed

LinkOut - more resources

Full Text Sources
- Europe PubMed Central
- PubMed Central

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Best practices: Appropriate use of the new β-lactam/β-lactamase inhibitor combinations, ceftazidime-avibactam and ceftolozane-tazobactam in South Africa

Affiliations

Best practices: Appropriate use of the new β-lactam/β-lactamase inhibitor combinations, ceftazidime-avibactam and ceftolozane-tazobactam in South Africa

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

References

LinkOut - more resources

Full Text Sources